{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:09:14Z","timestamp":1789794554416,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Introduction<\/jats:title>\n                <jats:p>Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and \/ or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup>, adapted to 2500\u00a0ng\/ml CDDP; UKF-PEC-1<jats:sup>r<\/jats:sup>5-FU<jats:sup>500<\/jats:sup>, adapted to 500\u00a0ng\/ml 5- FU; UKF-PEC1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup>\/<jats:sup>r<\/jats:sup>5-FU<jats:sup>500<\/jats:sup>, adapted to 2500\u00a0ng\/ml CDDP and 500\u00a0ng\/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup>, UKF-PEC-1<jats:sup>r<\/jats:sup>5-FU<jats:sup>500<\/jats:sup>, UKF-PEC1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup>\/<jats:sup>r<\/jats:sup>5-FU<jats:sup>500<\/jats:sup>, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results and conclusions<\/jats:title>\n                <jats:p>The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup> was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1<jats:sup>r<\/jats:sup>CDDP<jats:sup>2500<\/jats:sup> did not display sensitivity to PARP inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10432-7","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:06:01Z","timestamp":1671811561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Increased HRD score in cisplatin resistant penile cancer cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Ria","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Bankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Demes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Vallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"10432_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3238\/ARZTEBL.2018.0646","volume":"115","author":"OW Hakenberg","year":"2018","unstructured":"Hakenberg OW, Dr\u00e4ger DL, Erbersdobler A, Naumann CM, J\u00fcnemann KP, Protzel C. The Diagnosis and Treatment of Penile Cancer. Dtsch Arztebl Int Deutscher Arzte-Verlag GmbH. 2018;115:646. https:\/\/doi.org\/10.3238\/ARZTEBL.2018.0646. (cited 2021 Dec 3).","journal-title":"Dtsch Arztebl Int. Deutscher Arzte-Verlag GmbH."},{"issue":"14","key":"10432_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.UROLONC.2017.09.014","volume":"36","author":"K Attalla","year":"2018","unstructured":"Attalla K, Paulucci DJ, Blum K, Anastos H, Moses KA, Badani KK, Spiess PE, Sfakianos JP. Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer a report from the national cancer database. Urol Oncol Semin Orig Investig. 2018;36(14):17\u201314. https:\/\/doi.org\/10.1016\/J.UROLONC.2017.09.014. (Elsevier).","journal-title":"Urol Oncol Semin Orig Investig."},{"key":"10432_CR3","doi-asserted-by":"crossref","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter VE, International Agency for Research on Cancer. WHO classification of tumours of the urinary system and male genital organs. [cited 2018 May 3]. 356 p. Available from http:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Iarc-Classification-Of-Tumours\/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"10432_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0002-9440(10)62506-0","volume":"159","author":"MA Rubin","year":"2001","unstructured":"Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol Am Soc Invest Pathol. 2001;159:1211\u20138. https:\/\/doi.org\/10.1016\/S0002-9440(10)62506-0. (cited Jun 23 2019).","journal-title":"Am J Pathol Am Soc Invest Pathol"},{"key":"10432_CR5","unstructured":"Stratton KL. M, DJCDJ. A Contemporary Review of HPV and Penile Cancer | Cancer Network. Oncol (willist Park. 2016 [cited 2020 Dec 7]; . Available from https:\/\/www.cancernetwork.com\/view\/contemporary-review-hpv-and-penile-cancer"},{"key":"10432_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/PAS.0B013E3182113402","volume":"35","author":"A Chaux","year":"2011","unstructured":"Chaux A, Pfannl R, Rodr\u00edguez IM, Barreto JE, Velazquez EF, Lezcano C, Piris A, Netto GJ, Cubilla AL. Immunohistochemical profile of penile intraepithelial lesions: A study of 74 cases. Am J Surg Pathol. 2011;35:553\u201362. https:\/\/doi.org\/10.1097\/PAS.0B013E3182113402. (cited Dec 7 2021).","journal-title":"Am J Surg Pathol"},{"key":"10432_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000176016","volume":"82","author":"C Protzel","year":"2009","unstructured":"Protzel C, Hakenberg OW. Chemotherapy in patients with penile carcinoma. Urol Int Urol Int. 2009;82:1\u20137. https:\/\/doi.org\/10.1159\/000176016. (cited Apr 25 2022).","journal-title":"Urol Int. Urol Int."},{"key":"10432_CR8","doi-asserted-by":"publisher","unstructured":"Hussein AM, Benedetto P, Sridhar KS. Chemotherapy With Cisplatin and 5-Fluorouracil for Penile and Urethral Squamous Cell Carcinomas. doi: https:\/\/doi.org\/10.1002\/1097-0142.","DOI":"10.1002\/1097-0142"},{"key":"10432_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0022-5347(17)37327-5","volume":"147","author":"FV Shammas","year":"1992","unstructured":"Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol J Urol. 1992;147:630\u20132. https:\/\/doi.org\/10.1016\/S0022-5347(17)37327-5. (cited Apr 25 2022).","journal-title":"J Urol. J Urol"},{"key":"10432_CR10","doi-asserted-by":"publisher","first-page":"101267","DOI":"10.1016\/J.TRANON.2021.101267","volume":"15","author":"IA Bley","year":"2022","unstructured":"Bley IA, Zwick A, Hans MC, Thieser K, Wagner V, Ludwig N, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert C-I, Loertzer H, et al. IDKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells. Transl Oncol Neoplasia Press. 2022;15:101267. https:\/\/doi.org\/10.1016\/J.TRANON.2021.101267. (cited Dec 3 2021).","journal-title":"Transl Oncol. Neoplasia Press"},{"key":"10432_CR11","doi-asserted-by":"publisher","unstructured":"Kuasne H, Do Canto LM, Aagaard MM, Mu\u00f1oz JJM, De Jamblinne C, Marchi FA, Scapulatempo-Neto C, Faria EF, Lopes A, Carr\u00e9no S, Rogatto SR. Penile cancer-derived cells molecularly characterized as models to guide targeted therapies. Cells. MDPI 2021 10. doi: https:\/\/doi.org\/10.3390\/CELLS10040814\/S1.","DOI":"10.3390\/CELLS10040814\/S1"},{"key":"10432_CR12","doi-asserted-by":"publisher","unstructured":"Medeiros-Fonseca B, Cubilla A, Brito H, Martins T, Medeiros R, Oliveira P, Gil Da Costa RM. Experimental models for studying HPV-positive and HPV-negative penile cancer: New tools for an old disease. Cancers. MDPI AG; 2021 [cited 2021 May 5]. p. 1\u201315. doi: https:\/\/doi.org\/10.3390\/cancers13030460.","DOI":"10.3390\/cancers13030460"},{"key":"10432_CR13","doi-asserted-by":"publisher","unstructured":"Zhou QH, Deng CZ, Li ZS, Chen JP, Yao K, Huang KB, Liu TY, Liu ZW, Qin ZK, Zhou FJ, Huang W, Han H, Liu RY. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. Nature Publishing Group; 2018 [cited 2022 Mar 21]; 9. doi: https:\/\/doi.org\/10.1038\/S41419-018-0736-1.","DOI":"10.1038\/S41419-018-0736-1"},{"key":"10432_CR14","unstructured":"Ishikawa S, Kanoh S, Nemoto S. Establishment of a cell line (TSUS-1) derived from a human squamous cell carcinoma of the penis. Acta Urol Jpn. 1983 [cited 2022 Apr 27]; 29: 373\u20136. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/6587762\/"},{"key":"10432_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1620\/TJEM.88.9","volume":"88","author":"I Yamane","year":"1966","unstructured":"Yamane I, Tsuda T. Establishment of a cell line in vitro from the lesion of a clinical case of penis cancroid. Tohoku J Exp Med. 1966;88:9\u201320. https:\/\/doi.org\/10.1620\/TJEM.88.9. (cited May 2 2022).","journal-title":"Tohoku J Exp Med"},{"key":"10432_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2302\/KJM.38.277","volume":"38","author":"T Tsukamoto","year":"1989","unstructured":"Tsukamoto T. Establishment and characterization of a cell line KU-8 from squamous cell carcinoma of the penis. Keio J Med. 1989;38:277\u201393. https:\/\/doi.org\/10.2302\/KJM.38.277. (cited May 2 2022).","journal-title":"Keio J Med"},{"key":"10432_CR17","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/J.JURO.2012.01.035","volume":"187","author":"CM Naumann","year":"2012","unstructured":"Naumann CM, Sperveslage J, Hamann MF, Leuschner I, Weder L, Al-Najar AA, Lemke J, Sipos B, J\u00fcnemann KP, Kalthoff H. Establishment and characterization of primary cell lines of squamous cell carcinoma of the penis and its metastasis. J Urol. 2012;187:2236\u201342. https:\/\/doi.org\/10.1016\/J.JURO.2012.01.035. (cited May 2 2022).","journal-title":"J Urol"},{"key":"10432_CR18","doi-asserted-by":"publisher","first-page":"11375","DOI":"10.1007\/S13277-016-4951-Z","volume":"37","author":"JJ Mu\u00f1oz","year":"2016","unstructured":"Mu\u00f1oz JJ, Drigo SA, Kuasne H, Villacis RAR, Marchi FA, Domingues MAC, Lopes A, Santos TG, Rogatto SR. A comprehensive characterization of cell cultures and xenografts derived from a human verrucous penile carcinoma. Tumour Biol. 2016;37:11375\u201384. https:\/\/doi.org\/10.1007\/S13277-016-4951-Z.","journal-title":"Tumour Biol"},{"key":"10432_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/J.CCR.2012.07.016","volume":"22","author":"J Domingo-Domenech","year":"2012","unstructured":"Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells. Cancer Cell NIH Public Access. 2012;22:373. https:\/\/doi.org\/10.1016\/J.CCR.2012.07.016. (cited Dec 3 2021).","journal-title":"Cancer Cell. NIH Public Access"},{"key":"10432_CR20","doi-asserted-by":"publisher","unstructured":"Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol. AME Publishing Company; 2017 [cited 2021 Jan 2]; 6: 791\u2013802. https:\/\/doi.org\/10.21037\/tau.2017.06.27.","DOI":"10.21037\/tau.2017.06.27"},{"key":"10432_CR21","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1038\/cddis.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis M, Rothweiler F, Barth S, Cinat J, Van Rikxoort M, L\u00f6schmann N, Voges Y, Breitling R, Von Deimling A, R\u00f6del F, Weber K, Fehse B, MacK E, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2:e243. https:\/\/doi.org\/10.1038\/cddis.2011.129. (cited May 3 2021).","journal-title":"Cell Death Dis."},{"key":"10432_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/bju.13071","volume":"116","author":"G Aita","year":"2015","unstructured":"Aita G, da Costa WH, de Cassio Zequi S, da Cunha IW, Soares F, Guimaraes GC, Lopes A. Pattern of invasion is the most important prognostic factor in patients with penile cancer submitted to lymph node dissection and pathological absence of lymph node metastasis. BJU Int. 2015;116:584\u20139. https:\/\/doi.org\/10.1111\/bju.13071. (cited Jun 3 2019).","journal-title":"BJU Int."},{"key":"10432_CR23","doi-asserted-by":"publisher","unstructured":"Michaelis M, Wass MN, Cinatl J. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist. 2019 2; 447. https:\/\/doi.org\/10.20517\/CDR.2019.005.","DOI":"10.20517\/CDR.2019.005"},{"key":"10432_CR24","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/CANCERS13102323\/S1","volume":"13","author":"A Thomas","year":"2021","unstructured":"Thomas A, Reetz S, Stenzel P, Tagscherer K, Roth W, Schindeldecker M, Michaelis M, Rothweiler F, Cinatl J, Cinatl J, Dotzauer R, Vakhrusheva O, Albersen M, et al. Assessment of pi3k\/mtor\/akt pathway elements to serve as biomarkers and therapeutic targets in penile cancer. Cancers (Basel). 2021;13:2323. https:\/\/doi.org\/10.3390\/CANCERS13102323\/S1. (cited Nov 10 2022).","journal-title":"Cancers (Basel)"},{"key":"10432_CR25","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062-7. https:\/\/doi.org\/10.1093\/nar\/gkx1153. (cited May 3 2021).","journal-title":"Nucleic Acids Res."},{"key":"10432_CR26","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941-7. https:\/\/doi.org\/10.1093\/nar\/gky1015. (cited May 3 2021).","journal-title":"Nucleic Acids Res."},{"key":"10432_CR27","doi-asserted-by":"publisher","unstructured":"Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A, Szallasi Z. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npj Breast Cancer 2018 41. Nature Publishing Group; 2018 [cited 2022 Jan 11]; 4: 1\u20134. https:\/\/doi.org\/10.1038\/s41523-018-0066-6.","DOI":"10.1038\/s41523-018-0066-6"},{"key":"10432_CR28","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"LT Melinda","year":"2016","unstructured":"Melinda LT, Kirsten MT, Julia R, Bryan H, Gordon BM, Kristin CJ, Zoltan S, William TB, Eric PW, Nadine MT, Steven JI, Paula DR, April GC, et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477. (cited Jan 11 2022).","journal-title":"Clin Cancer Res."},{"key":"10432_CR29","doi-asserted-by":"publisher","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. Nat Commun; 2013 [cited 2022 Apr 27]; 4. https:\/\/doi.org\/10.1038\/NCOMMS3126.","DOI":"10.1038\/NCOMMS3126"},{"key":"10432_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/NRC2820","volume":"10","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241\u201353. https:\/\/doi.org\/10.1038\/NRC2820. (cited 2022 Apr 27).","journal-title":"Nat Rev Cancer."},{"key":"10432_CR31","doi-asserted-by":"publisher","unstructured":"Sheppard KE, Mcarthur GA. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. Clin Cancer Res. [cited 2021 Dec 10]; 19. doi: https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0259.","DOI":"10.1158\/1078-0432.CCR-13-0259"},{"key":"10432_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/MC.23185","volume":"59","author":"J Macedo","year":"2020","unstructured":"Macedo J, Silva E, Nogueira L, Coelho R, da Silva J, dos Santos A, Teixeira-J\u00fanior AA, Belfort M, Silva G, Khayat A, de Oliveira E, dos Santos AP, Cavalli LR, et al. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer. Mol Carcinog. 2020;59:604\u201317. https:\/\/doi.org\/10.1002\/MC.23185.","journal-title":"Mol Carcinog."},{"key":"10432_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2022.40.6_SUPPL.004","volume":"40","author":"B Nazha","year":"2022","unstructured":"Nazha B, Wu S, Brown JT, Magee D, Carthon BC, Kucuk O, Korn WM, Barata PC, Heath EI, Ryan CJ, McKay RR, Master VA, Bilen MA. Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers. Am Soc Clin Oncol. 2022;40:4\u20134. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_SUPPL.004. (cited Mar 1 2022).","journal-title":"Am Soc Clin Oncol"},{"key":"10432_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/THEONCOLOGIST.2015-0241","volume":"21","author":"SM Ali","year":"2016","unstructured":"Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncol. 2016;21:33. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2015-0241. (cited Mar 24 2022).","journal-title":"Oncol."},{"key":"10432_CR35","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/IJC.33990","volume":"150","author":"N Starita","year":"2022","unstructured":"Starita N, Pezzuto F, Sarno S, Losito NS, Perdon\u00e0 S, Buonaguro L, Buonaguro FM, Tornesello ML. Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients. Int J cancer Int J Cancer. 2022;150:1879\u201388. https:\/\/doi.org\/10.1002\/IJC.33990. (cited Mar 24 2022).","journal-title":"Int J cancer. Int J Cancer"},{"key":"10432_CR36","doi-asserted-by":"publisher","unstructured":"Ribera-Cortada I, Guerrero-Pineda J, Trias I, Veloza L, Garcia A, Marimon L, Diaz-mercedes S, Alamo JR, Rodrigo-calvo MT, Vega N, Del Campo RL, Parra-medina R, Ajami T, et al. Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review. Int J Mol Sci. Multidisciplinary Digital Publishing Institute (MDPI); 2022 [cited 2022 Feb 28]; 23. https:\/\/doi.org\/10.3390\/IJMS23010251.","DOI":"10.3390\/IJMS23010251"},{"key":"10432_CR37","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-L\u00f3pez S, Monsalve EM, Romero de \u00c1vila MJ, Gonz\u00e1lez-G\u00f3mez J, Hern\u00e1ndez de Le\u00f3n N, Ruiz-Marcos F, Baladr\u00f3n V, Nueda ML, Garc\u00eda-Le\u00f3n MJ, Screpanti I, Felli MP, Laborda J, Garc\u00eda-Ram\u00edrez JJ, et al. NOTCH3 signaling is essential for NF-\u03baB activation in TLR-activated macrophages. Sci Reports 2020 101. Nature Publishing Group; 2020 10: 1\u201316. https:\/\/doi.org\/10.1038\/s41598-020-71810-4.","DOI":"10.1038\/s41598-020-71810-4"},{"key":"10432_CR38","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/IJC.32373","volume":"145","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang K, Chen Y, Zhou J, Liang Y, Yang X, Li X, Cao Y, Wang D, Luo L, Li B, Li D, Wang L, et al. Mutational landscape of penile squamous cell carcinoma in a Chinese population. Int J Cancer. 2019;145:1280\u20139. https:\/\/doi.org\/10.1002\/IJC.32373. (cited Dec 10 2021).","journal-title":"Int J Cancer"},{"key":"10432_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/OR_00000692","volume":"23","author":"J-I Tanuma","year":"2010","unstructured":"Tanuma J-I, Izumo T, Hirano M, Oyazato Y, Hori F, Umemura E, Shisa H, Hiai H, Kitano M. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep. 2010;23:739\u201344. https:\/\/doi.org\/10.3892\/OR_00000692. (cited Mar 21 2022).","journal-title":"Oncol Rep."},{"key":"10432_CR40","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1038\/CDDIS.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis M, Rothweiler F, Barth S, Cinat J, Van Rikxoort M, L\u00f6schmann N, Voges Y, Breitling R, Von Deimling A, R\u00f6del F, Weber K, Fehse B, MacK E, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2:e243. https:\/\/doi.org\/10.1038\/CDDIS.2011.129. (cited Nov 4 2022).","journal-title":"Cell Death Dis"},{"key":"10432_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/10409238.2021.1881433","volume":"56","author":"SJ Young","year":"2021","unstructured":"Young SJ, West SC. Coordinated roles of SLX4 and MutS\u03b2 in DNA repair and the maintenance of genome stability. Crit Rev Biochem Mol Biol. 2021;56:157. https:\/\/doi.org\/10.1080\/10409238.2021.1881433. (cited Dec 20 2021).","journal-title":"Crit Rev Biochem Mol Biol."},{"key":"10432_CR42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4251\/WJGO.V14.I1.253","volume":"14","author":"W Zheng","year":"2022","unstructured":"Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol. 2022;14:253\u201364. https:\/\/doi.org\/10.4251\/WJGO.V14.I1.253.","journal-title":"World J Gastrointest Oncol."},{"key":"10432_CR43","doi-asserted-by":"publisher","first-page":"e154095","DOI":"10.1172\/JCI154095","volume":"131","author":"S Clark-Garvey","year":"2021","unstructured":"Clark-Garvey S, Kim WY. RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. J Clin Invest. 2021;131:e154095. https:\/\/doi.org\/10.1172\/JCI154095. (cited May 3 2022).","journal-title":"J Clin Invest."},{"key":"10432_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.LUNGCAN.2021.07.011","volume":"160","author":"F Wang","year":"2021","unstructured":"Wang F, Xi SY, Hao WW, Yang XH, Deng L, Xu YX, Wu XY, Zeng L, Guo KH, Wang HY. Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing. Lung Cancer. 2021;160:1\u20137. https:\/\/doi.org\/10.1016\/J.LUNGCAN.2021.07.011. (cited May 3 2022).","journal-title":"Lung Cancer"},{"key":"10432_CR45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/CANCERS14051245","volume":"14","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Mestre RP, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, et al. Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives. Cancers Basel). 2022;14:1245. https:\/\/doi.org\/10.3390\/CANCERS14051245. (cited May 3 2022).","journal-title":"Cancers Basel)."},{"key":"10432_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4155\/FMC-2020-0240","volume":"13","author":"S Tadesse","year":"2021","unstructured":"Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12\/13 inhibition for the treatment of cancer. Future Med Chem. 2021;13:117\u201341. https:\/\/doi.org\/10.4155\/FMC-2020-0240. (cited May 3 2022).","journal-title":"Future Med Chem."},{"key":"10432_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"SM Sweeney","year":"2017","unstructured":"Sweeney SM, Cerami E, Baras A, Pugh TJ, Schultz N, Stricker T, Lindsay J, Del Vecchio Fitz C, Kumari P, Micheel C, Shaw K, Gao J, Moore N, et al. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0151. (cited Feb 28 2022).","journal-title":"Cancer Discov"},{"key":"10432_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/S13046-021-02093-4","volume":"40","author":"T Rothenburger","year":"2021","unstructured":"Rothenburger T, Thomas D, Schreiber Y, Wratil PR, Pflantz T, Knecht K, Digianantonio K, Temple J, Schneider C, Baldauf HM, McLaughlin KM, Rothweiler F, Bilen B, et al. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 2021;40:317. https:\/\/doi.org\/10.1186\/S13046-021-02093-4. (cited Nov 4 2022).","journal-title":"J Exp Clin Cancer Res."},{"key":"10432_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/CANCERS12051080","volume":"12","author":"M Michaelis","year":"2020","unstructured":"Michaelis M, Wass MN, Reddin I, Voges Y, Rothweiler F, Hehlgans S, Cinatl J, Mernberger M, Nist A, Stiewe T, R\u00f6del F, Cinatl J. YM155-Adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting. Cancers basel. 2020;12:1080. https:\/\/doi.org\/10.3390\/CANCERS12051080. (cited Nov 4 2022).","journal-title":"Cancers basel"},{"key":"10432_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1010428317695931\/ASSET\/IMAGES\/LARGE\/10.1177_1010428317695931-FIG2.JPEG","volume":"39","author":"VV Palla","year":"2017","unstructured":"Palla VV, Karaolanis G, Katafigiotis I, Anastasiou I, Patapis P, Dimitroulis D, Perrea D. gamma-H2AX: Can it be established as a classical cancer prognostic factor? Tumor Biol. 2017;39:1\u201311. https:\/\/doi.org\/10.1177\/1010428317695931\/ASSET\/IMAGES\/LARGE\/10.1177_1010428317695931-FIG2.JPEG. (cited Nov 4 2022).","journal-title":"Tumor Biol"},{"key":"10432_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/CYTO.B.20450","volume":"76B","author":"PL Olive","year":"2009","unstructured":"Olive PL, Ban\u00e0th JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytom Part B Clin Cytom. 2009;76B:79\u201390. https:\/\/doi.org\/10.1002\/CYTO.B.20450. (cited Nov 4 2022).","journal-title":"Cytom Part B Clin Cytom"},{"key":"10432_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000495251","volume":"86","author":"R Stoehr","year":"2019","unstructured":"Stoehr R, Wendler O, Giedl J, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Bertz S, Hartmann A. No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis. Pathobiology. 2019;86:145\u201351. https:\/\/doi.org\/10.1159\/000495251. (cited May 3 2022).","journal-title":"Pathobiology"},{"key":"10432_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.2021.39.6_SUPPL.2","volume":"39","author":"PE Spiess","year":"2021","unstructured":"Spiess PE, Mata DA, Bratslavsky G, Jacob JM, Necchi A, Gjoerup O, Danziger N, Lin DI, Decker BJ, Sokol E, Huang R, Ross JS. Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study. Am Soc Clin Oncol. 2021;39:2\u20132. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_SUPPL.2.","journal-title":"Am Soc Clin Oncol"},{"key":"10432_CR54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/carcin\/bgy086","volume":"39","author":"A Gkountakos","year":"2018","unstructured":"Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, Tortora G, Scarpa A, Bria E, Corbo V. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis. 2018;39:971\u201380. https:\/\/doi.org\/10.1093\/carcin\/bgy086. (cited Dec 22 2021).","journal-title":"Carcinogenesis."},{"key":"10432_CR55","doi-asserted-by":"publisher","unstructured":"Kim SK, Kim JH, Han JH, Cho NH, Kim SJ, Kim S Il, Choo SH, Kim JS, Park B, Kwon JE. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features. J Cancer Res Clin Oncol. Springer; 2021 147: 1125. https:\/\/doi.org\/10.1007\/S00432-021-03514-9.","DOI":"10.1007\/S00432-021-03514-9"},{"key":"10432_CR56","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/BJC.2012.356","volume":"107","author":"J Ryan","year":"2012","unstructured":"Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O\u2019Meara A, Davidoff AM, Stallings RL. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012;107:967\u201376. https:\/\/doi.org\/10.1038\/BJC.2012.356. (cited May 2 2022).","journal-title":"Br J Cancer"},{"key":"10432_CR57","unstructured":"Lorenz M, Hermann M, Maike De Wit M, Tamm P-D. NTRK Inhibitoren Februar 2020 (korrigierte Version). [cited 2022 Mar 14]; . Available from www.dgho.de"},{"key":"10432_CR58","doi-asserted-by":"publisher","unstructured":"Adimonye A, Stankiewicz E, Kudahetti S, Trevisan G, Tinwell B, Corbishley C, Lu YJ, Watkin N, Berney D. Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway. Oncotarget. Impact Journals, LLC; 2018 9: 16074. https:\/\/doi.org\/10.18632\/ONCOTARGET.24688.","DOI":"10.18632\/ONCOTARGET.24688"},{"key":"10432_CR59","doi-asserted-by":"publisher","unstructured":"Fallahi H, Godini R. System-level responses to cisplatin in pro-apoptotic stages of breast cancer MCF-7 cell line. Comput Biol Chem. Comput Biol Chem; 2019 83. https:\/\/doi.org\/10.1016\/J.COMPBIOLCHEM.2019.107155.","DOI":"10.1016\/J.COMPBIOLCHEM.2019.107155"},{"key":"10432_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2017.63","volume":"2","author":"AD Whale","year":"2017","unstructured":"Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ. Functional characterization of a novel somatic oncogenic mutation of PIK3CB. Signal Transduct Target Ther. 2017;2:1\u20139. https:\/\/doi.org\/10.1038\/sigtrans.2017.63. (cited Mar 15 2022).","journal-title":"Signal Transduct Target Ther"},{"key":"10432_CR61","doi-asserted-by":"publisher","unstructured":"Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL. CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduct Target Ther. Signal Transduct Target Ther; 2021 [cited 2022 May 2]; 6. https:\/\/doi.org\/10.1038\/S41392-020-00437-8.","DOI":"10.1038\/S41392-020-00437-8"},{"key":"10432_CR62","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/NATURE09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235\u201341. https:\/\/doi.org\/10.1038\/NATURE09727. (cited May 2 2022).","journal-title":"Nature"},{"key":"10432_CR63","doi-asserted-by":"publisher","first-page":"12797","DOI":"10.2147\/OTT.S275688","volume":"13","author":"N Zhang","year":"2020","unstructured":"Zhang N, Shi J, Shi X, Chen W, Liu J. Mutational characterization and potential prognostic biomarkers of chinese patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2020;13:12797\u2013809. https:\/\/doi.org\/10.2147\/OTT.S275688. (cited May 2 2022).","journal-title":"Onco Targets Ther."},{"key":"10432_CR64","doi-asserted-by":"publisher","unstructured":"Rahman S, Canny MD, Buschmann TA, Latham MP. A Survey of Reported Disease-Related Mutations in the MRE11-RAD50-NBS1 Complex. Cells. Multidisciplinary Digital Publishing Institute (MDPI); 2020 [cited 2022 Mar 15]; 9. https:\/\/doi.org\/10.3390\/CELLS9071678.","DOI":"10.3390\/CELLS9071678"},{"key":"10432_CR65","doi-asserted-by":"publisher","unstructured":"Alblihy A, Alabdullah ML, Toss MS, Algethami M, Mongan NP, Rakha EA, Madhusudan S. RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers. Mol Biomed. Mol Biomed; 2020 [cited 2022 May 2]; 1. https:\/\/doi.org\/10.1186\/S43556-020-00023-Y.","DOI":"10.1186\/S43556-020-00023-Y"},{"key":"10432_CR66","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/J.SEMCDB.2011.07.019","volume":"22","author":"N Suwaki","year":"2011","unstructured":"Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol Elsevier Ltd. 2011;22:898\u2013905. https:\/\/doi.org\/10.1016\/J.SEMCDB.2011.07.019.","journal-title":"Semin Cell Dev Biol Elsevier Ltd"},{"key":"10432_CR67","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/1471-2407-13-484","volume":"13","author":"L Golmard","year":"2013","unstructured":"Golmard L, Caux-Moncoutier V, Davy G, Al Ageeli E, Poirot B, Tirapo C, Michaux D, Barbaroux C, d\u2019Enghien CD, Nicolas A, Cast\u00e9ra L, Sastre-Garau X, Stern MH, et al. Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer. 2013;13:484. https:\/\/doi.org\/10.1186\/1471-2407-13-484. (cited Mar 16 2022).","journal-title":"BMC Cancer"},{"key":"10432_CR68","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-06-4261","volume":"67","author":"LZ Liu","year":"2007","unstructured":"Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin\/p70S6K1 pathway. Cancer Res. 2007;67:6325\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4261. (cited Jan 11 2022).","journal-title":"Cancer Res"},{"key":"10432_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13577-021-00630-z","volume":"35","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang Z, Tang X, Zhang X, Chen Y, Hu T, Zhang H, Guan M, Zhang X, Wu Z. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. Hum Cell. 2022;35:199\u2013213. https:\/\/doi.org\/10.1007\/s13577-021-00630-z. (cited Mar 31 2022).","journal-title":"Hum Cell."},{"key":"10432_CR70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/S00292-021-00950-9\/FIGURES\/2","volume":"42","author":"N Pfarr","year":"2021","unstructured":"Pfarr N, Merkelbach-Bruse S. Homologous recombination repair deficiency as a predictive biomarker: Basic mechanisms and detection methods. Pathologe. 2021;42:391\u20138. https:\/\/doi.org\/10.1007\/S00292-021-00950-9\/FIGURES\/2. (cited Mar 29 2022).","journal-title":"Pathologe"},{"key":"10432_CR71","doi-asserted-by":"publisher","unstructured":"Hladek L, Bankov K, von der Gr\u00fcn J, Filmann N, Demes M, Vallo S, Wild PJ, Winkelmann R. Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas. Virchows Arch. Virchows Arch; 2022 [cited 2022 Mar 31]; https:\/\/doi.org\/10.1007\/S00428-022-03271-1.","DOI":"10.1007\/S00428-022-03271-1"},{"key":"10432_CR72","doi-asserted-by":"publisher","unstructured":"Vormittag-Nocito E, Groth J V., Mohapatra G. Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study. Pathol - Res Pract. Urban Fischer; 2020; 216 152863. https:\/\/doi.org\/10.1016\/J.PRP.2020.152863.","DOI":"10.1016\/J.PRP.2020.152863"},{"key":"10432_CR73","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","volume":"34","author":"TL Lotan","year":"2021","unstructured":"Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol. 2021;34:1185\u201393. https:\/\/doi.org\/10.1038\/s41379-020-00731-4. (cited Mar 29 2022).","journal-title":"Mod Pathol"},{"key":"10432_CR74","doi-asserted-by":"publisher","unstructured":"Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, H\u00fcbschmann D, Fr\u00f6hling S, et al. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency HRD. NPJ Precis Oncol 2022 6. https:\/\/doi.org\/10.1038\/S41698-022-00276-6.","DOI":"10.1038\/S41698-022-00276-6"},{"key":"10432_CR75","doi-asserted-by":"publisher","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front cell Dev Biol. 2020 8. https:\/\/doi.org\/10.3389\/FCELL.2020.564601.","DOI":"10.3389\/FCELL.2020.564601"},{"key":"10432_CR76","doi-asserted-by":"publisher","unstructured":"Gallyas F, Sumegi B, Szabo C. Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers Basel 2020 12. https:\/\/doi.org\/10.3390\/CANCERS12030532.","DOI":"10.3390\/CANCERS12030532"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10432-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10432-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10432-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:09:23Z","timestamp":1671811763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10432-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10432"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10432-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tissue samples and patient data used in this study were provided by the University Cancer Center Frankfurt (UCT). Written informed consent was obtained from all patients and the study was approved by the institutional review board of the UCT and the ethical committee at the University Hospital Frankfurt (project-number: SUG-02\u20132017) according to the declaration of Helsinki. For our studies, archived material was used in a double pseudonymized manner. Diagnostics were already finalised by the time of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable (NA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conflict of interest statement: PJW has received consulting fees and honoraria (private\/institutional) for lectures by Bayer, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers Squibb, Thermo Fisher Scientific, Molecular Health, Sophia Genetics, Qiagen, and Astra Zeneca. All other authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1352"}}